公开(公告)号：US20240335571A1

公开(公告)日：2024-10-10

申请号：US18676138

申请日：2024-05-28

Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Dexing ZENG ,  Lingyi SUN ,  Yongkang GAI

IPC: A61K51/08 ,  A61K9/51 ,  A61K47/68 ,  A61K51/10 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/50 ,  G01N33/60

CPC classification number: A61K51/082 ,  A61K9/51 ,  A61K47/6893 ,  A61K51/1027 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/5008 ,  G01N33/60 ,  C07K2319/00

Abstract: The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.

公开(公告)号：US12029798B2

公开(公告)日：2024-07-09

申请号：US16179785

申请日：2018-11-02

Applicant: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Dexing Zeng ,  Lingyi Sun ,  Yongkang Gai

IPC: A61K51/08 ,  A61K9/51 ,  A61K47/68 ,  A61K51/10 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/50 ,  G01N33/60

CPC classification number: A61K51/082 ,  A61K9/51 ,  A61K47/6893 ,  A61K51/1027 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/5008 ,  G01N33/60 ,  C07K2319/00

Abstract: The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.

公开(公告)号：US20240199588A1

公开(公告)日：2024-06-20

申请号：US18550178

申请日：2022-03-21

Applicant: The Hong Kong Polytechnic University

Inventor： Ga-Lai LAW

IPC: C07D403/14 ,  A61K49/00 ,  A61K49/10 ,  A61K51/04 ,  C07D255/02 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K49/0002 ,  A61K49/106 ,  A61K51/0482 ,  C07D255/02 ,  C07D401/14

Abstract: Cyclic 1,4,7-triazacyclononane-1,4,7-triacetic acid chelators and metal complexes comprising the same useful as positron emission tomography imaging agents, magnetic resonance imaging contrast agents, and computed tomography imaging agents, and optical imaging agents, and methods of use and preparation thereof.

公开(公告)号：US20230339869A1

公开(公告)日：2023-10-26

申请号：US18027829

申请日：2021-09-17

Applicant: Kyungpook National University Industry-Academic Cooperation Foundation

Inventor： Jae Sung Bae ,  Hee Kyung Jin ,  Min Hee Park

IPC: C07D255/02 ,  A61P3/02 ,  A61P1/00 ,  A61P3/14 ,  A61P21/00

CPC classification number: C07D255/02 ,  A61P3/02 ,  A61P1/00 ,  A61P3/14 ,  A61P21/00

Abstract: The present invention relates to a use of a triazole compound as a ghrelin receptor agonist and, more specifically, to a composition for preventing or treating diseases mediated by the ghrelin receptor, the composition being of a triazole compound which strongly binds to the ghrelin receptor with very high specificity. The compound provided by the present invention exhibits a strong binding force to the ghrelin receptor with very high specificity, and thus may be very usefully employed for preventing or developing a therapeutic agent for diseases mediated by the ghrelin receptor.

公开(公告)号：US20230183193A1

公开(公告)日：2023-06-15

申请号：US18054089

申请日：2022-11-09

Applicant: BAYER CROPSCIENCE AKTIENGESELLSCHAFT

Inventor： Hartmut AHRENS ,  Joerg TIEBES ,  Christian WALDRAFF ,  Hansjoerg DIETRICH ,  Elmar GATZWEILER ,  Christopher Hugh ROSINGER ,  Anu Bheemaiah MACHETTIRA

IPC: C07D257/04 ,  A01N43/26 ,  A01N43/653 ,  A01N43/82 ,  C07C317/14 ,  C07C321/28 ,  C07D255/02 ,  C07D271/04 ,  C07D271/06

CPC classification number: C07D257/04 ,  A01N43/26 ,  A01N43/653 ,  A01N43/82 ,  C07C317/14 ,  C07C321/28 ,  C07D255/02 ,  C07D271/04 ,  C07D271/06

Abstract: Benzoylamides of the general formula (I) are described as herbicides.




In this formula (I), X, R and Ra represent radicals such as alkyl, cycloalkyl and halogen. Q represents a five-membered heterocycle.

公开(公告)号：US11103604B2

公开(公告)日：2021-08-31

申请号：US14888908

申请日：2014-05-02

Applicant: GE Healthcare Limited ,  University of Southampton

Inventor： Rajiv Bhalla ,  Gill Reid ,  William Levason

IPC: A61K51/00 ,  A61M36/14 ,  A61K51/04 ,  C07F5/00 ,  C07D255/02

Abstract: A method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

公开(公告)号：US20210015802A1

公开(公告)日：2021-01-21

申请号：US17037103

申请日：2020-09-29

Applicant: FUJIFILM Corporation

Inventor： Hirofumi FUKUNAGA ,  Sachiko SHINJO ,  Daisuke NAKAGAWA ,  Shinichiro SEKINE ,  Takayuki YAMAKAWA

IPC: A61K31/4375 ,  A61K31/395 ,  A61K31/555 ,  C07F5/00 ,  C07D257/02 ,  C07D255/02 ,  C07F1/08 ,  C07D471/04 ,  A61K51/00 ,  C07B59/00 ,  A61K31/145 ,  A61K31/223 ,  A61K31/27 ,  A61K31/785 ,  C07D487/00

Abstract: A compound represented by Formula [3] or a salt thereof and a method of making the same, in the formula, L3 represents a group represented by Formula [2c] wherein R3c, R4c, R5c, and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6; A1 represents any one of the groups represented by Formulae [4] to [9], wherein * represents a binding position; and R7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

公开(公告)号：US20200216412A1

公开(公告)日：2020-07-09

申请号：US16723881

申请日：2019-12-20

Applicant: Rigel Pharmaceuticals, Inc.

Inventor： Matthew Duncton ,  Rajinder Singh

IPC: C07D401/04 ,  C07D257/04 ,  C07D255/02 ,  C07D249/12

Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

公开(公告)号：US10441669B2

公开(公告)日：2019-10-15

申请号：US15027104

申请日：2014-10-06

Applicant: ILLINOIS INSTITUTE OF TECHNOLOGY

Inventor： Hyun-Soon Chong

IPC: A61K51/00 ,  A61M36/14 ,  A61K51/04 ,  C07D401/12 ,  C07D255/02 ,  C07D257/02

Abstract: Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

公开(公告)号：US20180339071A1

公开(公告)日：2018-11-29

申请号：US15774632

申请日：2016-11-09

Applicant: CELLBION CO., LTD

Inventor： Jae Min Jeong ,  Sung-Hyun Moon ,  Yun-Sang Lee

IPC: A61K51/04 ,  C07D255/02 ,  C07F5/00 ,  C07D257/02 ,  A61P35/00

Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.